AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Talphera, Inc.

$1.24 +$0.08 (+6.90%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$1.24
Day Range
$1.21$1.25
Year Range
$0.69$1.57
Market Cap
64.36M
AVG Volume
267.61K
Trailing/Forward PE
-3.88/-
PEG ratio
-0.78
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
0200K400K600K800K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q21K
26 Q11K
25 Q428K
25 Q328K
25 Q227K
25 Q127K
24 Q40
24 Q3281K
24 Q2398K
24 Q1651K
Net Income (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-15.08M
26 Q1-14.25M
25 Q4-14.29M
25 Q3-12.39M
25 Q2-11.3M
25 Q1-11.64M
24 Q4-13M
24 Q3-15.65M
24 Q2-13.65M
24 Q1-14.2M
Operating Income (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-14.75M
26 Q1-14.52M
25 Q4-13.48M
25 Q3-13.03M
25 Q2-13.35M
25 Q1-13.93M
24 Q4-15.25M
24 Q3-16.54M
24 Q2-16.1M
24 Q1-15.8M
EBITDA (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-14.13M
26 Q1-14.25M
25 Q4-11.45M
25 Q3-9.52M
25 Q2-8.41M
25 Q1-8.52M
24 Q4-12.51M
24 Q3-15.18M
24 Q2-13.27M
24 Q1-14.04M
Cash Flows (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-12.27M
26 Q1-11.29M
25 Q4-11.36M
25 Q3-11.18M
25 Q2-11.61M
25 Q1-13.27M
24 Q4-12.68M
24 Q3-14.38M
24 Q2-14.3M
24 Q1-15.03M
EPS (USD) · TTM
-1-0.75-0.5-0.25024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-0.32
26 Q1-0.36
25 Q4-0.4
25 Q3-0.38
25 Q2-0.4
25 Q1-0.45
24 Q4-0.51
24 Q3-0.69
24 Q2-0.64
24 Q1-0.9
Expenses (USD) · TTM
-5M05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q214.75M
26 Q114.52M
25 Q411.74M
25 Q39.61M
25 Q28.24M
25 Q16.45M
24 Q46.72M
24 Q37.16M
24 Q26.19M
24 Q15.83M
Shares Outstanding (USD) · TTM
-2M02M4M6MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TLPH Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-802K
26 Q1-722K
25 Q4-704K
25 Q35.13M
25 Q25.06M
25 Q15M
24 Q44.89M
24 Q3-1.07M
24 Q2-833K
24 Q1-1.08M
Employee Count
05101520242025
TLPH Employee Count by quarter
PeriodEmployee Count
202512
202413
PE Ratio
00.250.50.751med 0.27Sep 22Nov 22Jan 23Mar 23May 23Jun 23Aug 23
TLPH PE Ratio by quarter
PeriodPE Ratio
Aug 230.25
Aug 230.2
Aug 230.2
Aug 230.22
Jul 230.22
Jul 230.23
Jul 230.27
Jul 230.29
Jun 230.25
Jun 230.25
Jun 230.27
Jun 230.28
Jun 230.23
May 230.17
May 230.12
May 230.12
May 230.1
Apr 230.1
Apr 230.11
Apr 230.11
Apr 230.1
Mar 230.1
Mar 230.11
Mar 230.1
Mar 230.18
Mar 230.2
Feb 230.22
Feb 230.24
Feb 230.27
Feb 230.32
Jan 230.31
Jan 230.35
Jan 230.4
Jan 230.34
Dec 220.35
Dec 220.32
Dec 220.37
Dec 220.33
Dec 220.35
Nov 220.38
Nov 220.39
Nov 220.33
Nov 220.31
Oct 220.45
Oct 220.65
Oct 220.71
Oct 220.65
Sep 220.68
Sep 220.78
Sep 220.9
Sep 220.9
Sep 220.97
Free Cash Flow Yield
-150%-100%-50%0%med -35.95%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TLPH Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-13.1%
Sep 26-13.1%
Sep 26-13.54%
Aug 26-13.54%
Aug 26-13.65%
Aug 26-13.21%
Aug 26-18.62%
Jul 26-20.8%
Jul 26-19.73%
Jul 26-20.02%
Jul 26-18.24%
Jul 26-24.89%
Jun 26-25.85%
Jun 26-24.43%
Jun 26-30.49%
Jun 26-34.36%
May 26-32.63%
May 26-32.67%
May 26-31.4%
May 26-29.65%
May 26-29.17%
Apr 26-34.57%
Apr 26-33.39%
Apr 26-35.23%
Apr 26-37.1%
Mar 26-36.14%
Mar 26-32.39%
Mar 26-33.85%
Mar 26-31.09%
Feb 26-29.59%
Feb 26-34.73%
Feb 26-33.27%
Feb 26-33.13%
Jan 26-28.22%
Jan 26-26.98%
Jan 26-26.97%
Jan 26-25.45%
Jan 26-23.25%
Dec 25-24.52%
Dec 25-24.52%
Dec 25-22.67%
Dec 25-21.93%
Nov 25-20.28%
Nov 25-20.13%
Nov 25-21.58%
Nov 25-27.11%
Oct 25-25.09%
Oct 25-29.23%
Oct 25-31.42%
Oct 25-27.33%
Oct 25-35.39%
Sep 25-37.09%
Sep 25-39.55%
Sep 25-35.76%
Sep 25-61.21%
Aug 25-62.14%
Aug 25-68.23%
Aug 25-79.03%
Aug 25-123.36%
Aug 25-125.54%
Jul 25-119.4%
Jul 25-123.24%
Jul 25-97.15%
Jul 25-112.01%
Jun 25-107.94%
Jun 25-110.91%
Jun 25-103.1%
Jun 25-99.05%
May 25-102.89%
May 25-99.84%
May 25-100.23%
May 25-89.53%
May 25-90.37%
Apr 25-99.46%
Apr 25-101.76%
Apr 25-96.68%
Apr 25-94.61%
Mar 25-93.6%
Mar 25-86.42%
Mar 25-97.95%
Mar 25-99.73%
Feb 25-98.04%
Feb 25-91.34%
Feb 25-81.87%
Feb 25-84.39%
Jan 25-86.38%
Jan 25-80.66%
Jan 25-81.87%
Jan 25-91.42%
Jan 25-88.44%
Dec 24-103.49%
Dec 24-86.34%
Dec 24-84.39%
Dec 24-79.38%
Nov 24-77.59%
Nov 24-78.91%
Nov 24-79.48%
Nov 24-60.11%
Nov 24-59.32%
Oct 24-56.08%
Price to Sales
0250005000075000100000med 1150.9Nov 24Feb 25Jul 25Nov 25Feb 26Jun 26Sep 26
TLPH Price to Sales by quarter
PeriodPrice to Sales
Sep 2693653.36
Sep 2693653.36
Sep 2690632.28
Aug 2690632.28
Aug 2689877.01
Aug 2692898.09
Aug 2660647.32
Jul 2654285.71
Jul 2657254.46
Jul 2656406.25
Jul 2661919.64
Jul 2645379.46
Jun 2643683.03
Jun 2646227.67
Jun 2637041.51
Jun 2632868.3
May 2634607.14
May 2634568.97
May 2635964.28
May 261368.81
May 261391.37
Apr 261173.87
Apr 261215.67
Apr 261152.06
Apr 261094.04
Mar 261123.13
Mar 261233.09
Mar 261179.64
Mar 261284.31
Feb 261349.6
Feb 261149.74
Feb 261200.37
Feb 261205.41
Jan 261415.34
Jan 261480.33
Jan 261480.48
Jan 261569.31
Jan 261717.35
Dec 251628.53
Dec 251628.53
Dec 251761.77
Dec 251820.99
Nov 251969.04
Nov 251983.84
Nov 251850.6
Nov 251585.84
Oct 251713.73
Oct 251470.74
Oct 251368.43
Oct 251573.05
Oct 251214.96
Sep 251159.2
Sep 251087.07
Sep 251202.17
Sep 25702.37
Aug 25691.89
Aug 25630.12
Aug 25543.98
Aug 25398.4
Aug 25391.49
Jul 25411.63
Jul 25398.79
Jul 25505.91
Jul 25438.78
Jun 25455.32
Jun 25443.15
Jun 25476.72
Jun 25496.18
May 25477.69
May 25492.29
May 25490.34
Mar 2554.66
Mar 2559.21
Mar 2552.24
Mar 2551.31
Feb 2552.19
Feb 2556.02
Feb 2562.5
Feb 2560.63
Jan 2559.24
Jan 2563.43
Jan 2562.5
Jan 2555.97
Jan 2557.85
Dec 2449.44
Dec 2459.26
Dec 2460.63
Dec 2464.46
Nov 2465.95
Nov 2464.84
Nov 2464.38
Nov 2459.78
Nov 2460.57
Oct 2464.07
Oct 2472.42
Oct 2452.01
Oct 2451.35
Sep 2456.55
Sep 2460.53
Sep 2459.25
EV/EBITDA
-0.200.20.40.60.8med 0.08Sep 22Nov 22Jan 23Mar 23May 23Jun 23Aug 23
TLPH EV/EBITDA by quarter
PeriodEV/EBITDA
Aug 230.03
Aug 23-0.01
Aug 23-0.01
Aug 230.01
Jul 230.01
Jul 230.02
Jul 230.05
Jul 230.06
Jun 230.03
Jun 230.03
Jun 230.04
Jun 230.05
Jun 230.02
May 230.04
May 230
May 230
May 23-0.01
Apr 23-0.01
Apr 23-0.01
Apr 23-0.01
Apr 23-0.02
Mar 23-0.01
Mar 23-0.01
Mar 23-0.01
Mar 230.05
Mar 230.07
Feb 230.11
Feb 230.13
Feb 230.16
Feb 230.2
Jan 230.19
Jan 230.22
Jan 230.26
Jan 230.21
Dec 220.22
Dec 220.2
Dec 220.24
Dec 220.2
Dec 220.22
Nov 220.16
Nov 220.16
Nov 220.12
Nov 220.1
Oct 220.21
Oct 220.37
Oct 220.42
Oct 220.37
Sep 220.4
Sep 220.48
Sep 220.58
Sep 220.58
Sep 220.63
Price to Book
02468med 2.04Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TLPH Price to Book by quarter
PeriodPrice to Book
Sep 266.5
Sep 266.5
Sep 266.29
Aug 266.29
Aug 266.24
Aug 266.45
Aug 263.28
Jul 262.94
Jul 263.1
Jul 263.05
Jul 263.35
Jul 262.46
Jun 262.36
Jun 262.5
Jun 262
Jun 261.78
May 261.87
May 261.87
May 261.95
May 262.25
May 262.29
Apr 261.93
Apr 262
Apr 261.89
Apr 261.8
Mar 261.85
Mar 261.8
Mar 261.72
Mar 261.88
Feb 261.97
Feb 261.68
Feb 261.75
Feb 261.76
Jan 262.07
Jan 262.16
Jan 262.16
Jan 262.29
Jan 262.51
Dec 252.38
Dec 252.38
Dec 252.57
Dec 252.66
Nov 252.87
Nov 252.9
Nov 252.7
Nov 256.46
Oct 256.98
Oct 255.99
Oct 255.58
Oct 256.41
Oct 254.95
Sep 254.72
Sep 254.43
Sep 254.9
Sep 252.86
Aug 252.82
Aug 252.57
Aug 252.22
Aug 251.92
Aug 251.89
Jul 251.99
Jul 251.92
Jul 252.44
Jul 252.12
Jun 252.2
Jun 252.14
Jun 252.3
Jun 252.39
May 252.3
May 252.37
May 252.36
May 251.77
May 251.75
Apr 251.59
Apr 251.56
Apr 251.64
Apr 251.68
Mar 251.59
Mar 251.73
Mar 251.52
Mar 251.5
Feb 251.52
Feb 251.63
Feb 251.82
Feb 251.77
Jan 251.73
Jan 251.85
Jan 251.82
Jan 251.63
Jan 251.69
Dec 241.44
Dec 241.73
Dec 241.77
Dec 241.88
Nov 241.92
Nov 241.89
Nov 241.88
Nov 241.87
Nov 241.89
Oct 242
Talphera, Inc.
TLPH
Stockpicker

Video analysis: TLPH

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: TLPH

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

prnewswire.com · 3 Sep 2026

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Company management will be presenting at the H.C.

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

seekingalpha.com · 13 Aug 2026

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

prnewswire.com · 12 Aug 2026

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of $17.1 million at June 30, 2026 Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced financial results for the second quarter of 2026 and provided a corporate update on the development of nafamostat.

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

prnewswire.com · 5 Aug 2026

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.